Private Advisor Group’s Fortress Biotech FBIO Stock Holding History

Private Advisor Group’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-72	Closed	-$3K	–	2181
2020 Q2	$3K	Buy	+72	New	+$2.67K	﹤0.01%	3430

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Advisor Group's FBIO Position: Q3 2020 in Review

Private Advisor Group sold out of Fortress Biotech (FBIO) in Q3 2020, closing a stake of 72 shares — an estimated $3K sold.

Private Advisor Group first reported a position in FBIO in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 77 funds tracked by Wall St. Rank hold FBIO as of Q3 2020.

Private Advisor Group reported no remaining Fortress Biotech position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 72 Fortress Biotech shares in Q3 2020, an estimated $3K.
Private Advisor Group first reported a position in Fortress Biotech in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Fortress Biotech position peaked at $3K in Q2 2020.
77 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.